Send to

Choose Destination

See 1 citation in Transl Lung Cancer Res 2015:

Transl Lung Cancer Res. 2015 Apr;4(2):110-8. doi: 10.3978/j.issn.2218-6751.2015.01.01.

Epidermal growth factor receptor in non-small cell lung cancer.

Author information

Department of Respiratory Medicine, Royal Prince Alfred Hospital, NSW 2050, Australia.


Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI) trials for lung cancer, there has been detailed focus on which patients may benefit from inhibitor therapy. This article reviews the background, genetics and prevalence of epidermal growth factor mutations in non-small cell lung cancer (NSCLC). Additionally, the prevalence in unselected patients is compared against various other reviews.


Lung neoplasms; carcinoma; epidermal growth factor; non-small cell lung cancer (NSCLC); receptor

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center